Figure 5.

Selective deletion of Nhe1 in CX3CR1⁺Nhe1 KO mice altered glioma tumor immunity. (A) Tamoxifen-induced selective knockout of Nhe1 in Cx3Cr1-Cre^ERT2+/-; Nhe1^f/f mice (Nhe1 KO). Tam-treated Cx3Cr1-Cre^ERT2-/-;Nhe1^f/f were used as control group (Con). SB28-GFP cells were intracranially transplanted in Con and Nhe1 KO mice at postnatal 60 days (P60). Mice were treated with either Veh or TMZ. (B) Representative FACS gating strategy of microglia (CD11b⁺/CD45^low-medium) or infiltrated myeloid cells (CD11b⁺/CD45^hi). (C) Inflammatory profile of CD11b⁺/CD45^low-medium and CD11b⁺/CD45^hi population. (D) Changes of infiltrated CD8⁺, CD8⁺GZMb⁺ and CD8⁺IFNγ⁺ profiles. (E) Percentages of PD-1⁺ and CTLA-4⁺ cells in the CD8⁺ T-cell populations. (F) Changes of CD4⁺, CD4⁺GZMb⁺, CD4⁺IFNγ⁺ and CD4⁺CD25⁺FoxP3⁺ (Treg) profiles and (G) Percentages of PD-1⁺ and CTLA-4⁺ cells in the CD4⁺ T-cell populations. Data are mean ± SEM, n = 4-5 mice/group. *p < 0.05 vs indicated.